Clinicians should understand how amphetamine and methylphenidate differ in respect to their: risks of psychosis, mania, and substance use, neurotoxic and neuroprotective properties, efficacy and tolerability, and use across the lifespan.

How to have a discussion with patients and to document risks and benefits to educate them the baseline risk of depression treatment in pregnancy.